Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CFDA

- PMLiVE

Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence

More than 5,000 patients in England are expected to be eligible for the anti-PD-1 therapy

- PMLiVE

AstraZeneca/Ionis’ Wainzua receives positive CHMP opinion to treat rare disease ATTRv-PN

The drug can be self-administered via an auto-injector and is designed to lower the production of TTR protein at its source

- PMLiVE

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer

Just under 100 non-small cell lung cancer patients in England will be eligible for the drug

- PMLiVE

AstraZeneca receives MHRA approval for Wainzua in rare nerve disease ATTRv-PN

The therapy is designed to reduce the effects of the disease by lowering the production of TTR protein

- PMLiVE

AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra

The chronic respiratory disease is estimated to affect up to 262 million people globally

- PMLiVE

AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn

Dyslipidaemia is estimated to result in 2.6 million global deaths every year

- PMLiVE

Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC

More than 200,000 people are diagnosed with lung cancer in the US every year

- PMLiVE

AstraZeneca’s Tagrisso approved by FDA to treat EGFR-mutated lung cancer

More than 200,000 people are diagnosed with lung cancer in the US every year

- PMLiVE

J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC

Alterations in EGFR are among the most common driver mutations in lung cancer patients

- PMLiVE

Merck/Daiichi Sankyo’s ADC candidate shows promise in phase 3 lung cancer trial

EGFR-activating mutations occur in up to 38% of all NSCLC tumours globally

- PMLiVE

AstraZeneca’s Fasenra receives FDA approval to treat rare inflammatory disease EGPA

Eosinophilic granulomatosis with polyangiitis affects approximately 15,000 people in the US

- PMLiVE

J&J’s Rybrevant combination shows positive overall survival trend in late-stage lung cancer study

Alterations in EGFR are among the most common driver mutations in NSCLC patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links